TY - JOUR
T1 - DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer
AU - Sinicrope, Frank A.
PY - 2010/3
Y1 - 2010/3
N2 - Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.
AB - Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.
UR - http://www.scopus.com/inward/record.url?scp=77749277597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77749277597&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2009.235
DO - 10.1038/nrclinonc.2009.235
M3 - Comment/debate
C2 - 20190798
AN - SCOPUS:77749277597
SN - 1759-4774
VL - 7
SP - 174
EP - 177
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 3
ER -